Larimar Therapeutics, Inc. filed a Form S-8 registration statement with the SEC on November 16, 2026, to register 850,000 shares of common stock issuable under equity inducement awards granted to one newly hired employee on September 29, 2026.
Key Highlights
- Stock options: The company granted options to purchase 800,000 shares of common stock to a single newly hired employee.
- Restricted stock units: An additional 50,000 shares of common stock were covered by restricted stock unit inducement awards granted to the same employee.
- Grant date: Both awards were granted on September 29, 2026.
- Compensation Committee approval: The awards were approved by the Registrant's Compensation Committee of the Board of Directors in reliance on Nasdaq Listing Rule 5635(c)(4).
- Outside existing plans: The Inducement Awards were granted outside of the Registrant's 2020 Equity Incentive Plan and its predecessor plans.
- Par value: The shares registered are common stock with a par value of $0.001 per share.
Larimar Therapeutics Registers Inducement Equity for Newly Hired Employee
Larimar Therapeutics, Inc. (NASDAQ:LRMR), a Delaware corporation headquartered in Bala Cynwyd, Pennsylvania, filed a Form S-8 registration statement on November 16, 2026, to register shares underlying equity inducement awards. According to the filing, the awards were made to induce one newly hired employee to accept employment with the company. The total shares registered amount to 850,000, comprising 800,000 shares subject to stock options and 50,000 shares subject to restricted stock units, all granted on September 29, 2026.
The filing states that the Inducement Awards were approved by the Registrant's Compensation Committee of the Board of Directors "in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4)." This rule provides a framework allowing listed companies to grant equity awards outside of stockholder-approved plans as an inducement for new hires. The filing explicitly notes that the awards were granted outside of the Registrant's 2020 Equity Incentive Plan and its predecessor plans.
The registration statement incorporates by reference previously filed documents, including the company's Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2026, and various Current Reports on Form 8-K filed through November 9, 2026. Larimar Therapeutics is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
What Was Disclosed
Larimar Therapeutics filed a Form S-8 on November 16, 2026, registering 850,000 shares of common stock (par value $0.001) issuable under stock option and restricted stock unit inducement awards granted September 29, 2026, to one newly hired employee, outside the company's existing equity incentive plan.




Please wait processing your request...